Japan's Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for adults with moderate-to-severe bullous pemphigoid, making it the first targeted therapy for this rare disease. The Sanofi/Regeneron label expansion should modestly boost Dupixent sales in Japan and strengthen the drug's global franchise; expect a potential ~1-3% move in the companies' shares on the news.
Japan's Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for adults with moderate-to-severe bullous pemphigoid, making it the first targeted therapy for this rare disease. The Sanofi/Regeneron label expansion should modestly boost Dupixent sales in Japan and strengthen the drug's global franchise; expect a potential ~1-3% move in the companies' shares on the news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
